Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-75 vs TYLOX
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Tylox combines oxycodone, a mu-opioid receptor agonist, with acetaminophen, which inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).
Management of moderate to moderately severe pain (FDA),Off-label: not typically used due to fixed combination
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
1-2 capsules (oxycodone 5 mg/acetaminophen 325 mg) orally every 6 hours as needed for pain; maximum 12 capsules per day.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Oxycodone: 3.5-5.6 hours; acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged up to 13 hours.
Primarily metabolized via CYP3A4 in the liver and intestinal mucosa to norfentanyl and other minor metabolites; undergoes extensive first-pass metabolism.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Reduce dose by 50% and monitor.
GFR 30-50 m L/min: administer 75% of usual dose every 6 hours; GFR 10-29 m L/min: 50% of usual dose every 6 hours; GFR <10 m L/min: 25-50% of usual dose every 12 hours.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use.
Risk of respiratory depression that may result in death; ensure proper patient selection, dosing, and monitoring. Avoid use in opioid non-tolerant patients. Accidental exposure can be fatal. Concomitant use with CNS depressants increases risk. Risk of abuse, misuse, addiction, and diversion. Neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of life-threatening respiratory depression from CYP3A4 inhibitors or discontinuation of CYP3A4 inducers.
Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS) postpartum. Use during labor may cause respiratory depression in neonate. Risk of preterm birth and low birth weight with prolonged use.
Pregnancy Category C. First trimester: acetaminophen is generally considered safe; oxycodone has shown teratogenic effects in animal studies at high doses, but human data are limited. Second and third trimesters: chronic oxycodone use may lead to neonatal opioid withdrawal syndrome (NOWS). There is no evidence of major malformations with standard therapeutic doses.
DURAGESIC-75 delivers fentanyl at 75 mcg/hour transdermally. Do not use in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-hairy skin on upper torso or upper arm. Avoid heat sources (heating pads, hot tubs) as heat increases absorption. Onset ~12-24 hours; peak effect ~24-72 hours. Remove old patch before applying new; rotate sites. Do not cut or damage the patch. Monitor for serotonin syndrome if used with serotonergic drugs. For breakthrough pain, use immediate-release opioids not additional fentanyl patches.
Avoid concurrent use with other acetaminophen-containing products to prevent hepatotoxicity. Maximum acetaminophen dose is 4 g/day (3 g/day in chronic alcohol use). Monitor for respiratory depression, especially in elderly or opioid-naive patients. Use with caution in patients with hepatic impairment or severe renal dysfunction. Oxycodone has abuse potential; prescribe smallest quantity for shortest duration.
No interactions on record
No interactions on record
DURAGESIC-75 and TYLOX are distinct pharmacological agents. DURAGESIC-75 belongs to the Opioid Analgesic class and is primarily used for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).. TYLOX belongs to the Opioid analgesic combination class and is primarily used for Management of moderate to moderately severe pain (FDA)Off-label: not typically used due to fixed combination. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURAGESIC-75 carries a safety status of Category C, whereas TYLOX safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Oxycodone is metabolized primarily via CYP3A4 and CYP2D6; acetaminophen is metabolized in the liver via conjugation (glucuronidation, sulfation) and CYP2E1 for a minor toxic metabolite (NAPQI).
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Renal: oxycodone ~19% unchanged; acetaminophen ~2-5% unchanged. Biliary: minimal. Fecal: <5% total. Total renal elimination: ~60-70% as metabolites of oxycodone (noroxycodone, oxymorphone) and acetaminophen conjugates.
90-95% bound to alpha-1-acid glycoprotein and albumin
Oxycodone: 38-45% primarily to albumin; acetaminophen: 10-25%.
6-7 L/kg, indicating extensive tissue distribution
Oxycodone: 2.6 L/kg (large, indicates extensive tissue distribution); acetaminophen: 0.9 L/kg.
Fentanyl transdermal: 50-65% of patch content absorbed into systemic circulation
Oral: oxycodone 60-87% (first-pass metabolism); acetaminophen 63-89%.
Child-Pugh A: reduce dose by 50% and consider extended interval; Child-Pugh B: 25-50% of usual dose every 8-12 hours; Child-Pugh C: contraindicated or use with extreme caution at 25% of dose every 12 hours.
Children ≥2 years: 12.5-25 mcg/hr initial, titrate based on need; max dose 25 mcg/hr for opioid-naive.
Children ≥11 years: 1 capsule (oxycodone 5 mg/acetaminophen 325 mg) orally every 6 hours as needed; maximum 4 doses per day. For children <11 years: weight-based dosing of oxycodone 0.05-0.15 mg/kg/dose (max 5 mg) and acetaminophen 10-15 mg/kg/dose (max 650 mg) every 4-6 hours; use appropriate separate formulations.
Initial dose reduction of 25-50%; titrate cautiously; avoid in frail elderly.
Initiate at 50% of adult dose (e.g., 1 capsule every 8-12 hours) and titrate cautiously due to increased sensitivity and risk of adverse effects; monitor renal and hepatic function.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interactions with CNS depressants; and hepatotoxicity from acetaminophen overdose.
Risk of respiratory depression, opioid-induced hyperalgesia, hypotension, adrenal insufficiency, serotonin syndrome, severe hypotension, and hepatotoxicity; avoid abrupt discontinuation; use with caution in elderly, debilitated, or those with pulmonary disease.
Hypersensitivity, significant respiratory depression, acute or severe bronchial asthma, GI obstruction, known or suspected paralytic ileus, and severe hepatic impairment (acetaminophen component).
No significant food interactions. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition; caution with high intake. Avoid alcohol due to additive CNS depression.
Avoid alcohol. Grapefruit juice may increase oxycodone levels; limit or avoid consumption. High-fat meals may delay absorption but do not significantly alter overall exposure.
Fentanyl is excreted in breast milk. M/P ratio approximately 0.4. Breastfeeding is generally not recommended during Duragesic-75 use due to risk of infant sedation and respiratory depression. If used, monitor infant for unusual sleepiness, difficulty breathing, or poor feeding. Alternative analgesics are preferred.
Acetaminophen and oxycodone are excreted into breast milk. Oxycodone M/P ratio is approximately 3.6:1. At maternal therapeutic doses, infant exposure is low but may cause sedation or respiratory depression. Caution advised; monitor infant for signs of opioid toxicity. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution.
No specific dose adjustments are established for Duragesic-75 in pregnancy. Fentanyl pharmacokinetics may be altered due to increased plasma volume, renal clearance, and hepatic metabolism; however, transdermal absorption may be inconsistent. Use lowest effective dose for shortest duration. Consider alternative opioids with more pregnancy data. Taper dose before delivery to reduce NAS risk.
Increased renal clearance and volume of distribution during pregnancy may reduce acetaminophen and oxycodone serum concentrations. Dose adjustments may be needed for adequate analgesia; monitor and titrate to effect. No established dosing guidelines; individualize based on pain severity and response. Avoid long-term use; use lowest effective dose for shortest duration.
Apply the patch to a flat, non-hairy area of the upper body or arm. Do not use on skin that is irritated, cut, or scarred.,Do not expose the patch to direct heat sources like heating pads, electric blankets, hot tubs, or sunbathing—this can cause a dangerous overdose.,Wash hands after handling the patch. Dispose of used patches by folding sticky sides together and flushing down toilet per FDA guidelines.,Remove the old patch and apply the new patch to a different skin site every 72 hours (3 days). Rotate sites to avoid skin irritation.,Do not cut, chew, or damage the patch—this can lead to rapid release of fentanyl and fatal overdose.,Store patches in a secure place away from children and pets. Accidental exposure can be fatal.,Common side effects include nausea, vomiting, constipation, dizziness, and drowsiness. Report severe drowsiness, confusion, difficulty breathing, or signs of an allergic reaction.,Avoid alcohol, other opioids, benzodiazepines, and sedatives as they increase risk of respiratory depression.,Do not stop using this medication suddenly; taper with prescriber to avoid withdrawal symptoms.,Seek emergency care for symptoms of overdose: slow or shallow breathing, extreme drowsiness, or unresponsiveness.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take with other acetaminophen products (e.g., Tylenol, cold medications) to avoid liver damage.,Avoid alcohol while taking TYLOX; it increases risk of liver injury.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how TYLOX affects you.,Store securely away from children; accidental overdose can be fatal.,Do not share this medication with others; it can cause serious harm or addiction.,If you miss a dose, skip it and take next dose at regular time; do not double dose.,Seek emergency help if you experience slow breathing, severe drowsiness, or fainting.